Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Therapeutic dosing of busulfan helps reduce relapse in ASCT

Publish date:: March 13, 2019

Key clinical point: Pharmacokinetic-directed therapeutic dose monitoring (PK-TDM) of busulfan reduced relapse rates compared with weight-based dosing (WBD) in non-Hodgkin lymphoma patients undergoing ASCT.

Major finding: Relapse rate at 24 months after ASCT was 19% vs. 38% with PK-TDM vs. WBD.

Study details: A retrospective review of 336 cases.

Disclosures: Dr. Hill reported having no relevant financial disclosures.

Citation:

Hill B et al. TCT 2019, Abstract 39.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,